Board
Corporate Leadership Team
Rob McKenzie LL.B; B.Juris, FAICD
Non-Executive Chairperson
Rob is a lawyer with over 35 years’ experience in corporate and commercial transactions, restructuring and dispute resolution. He has advised companies on mergers and acquisitions; floats; corporate structuring and restructuring; corporate governance; board and meeting compliance and investment and financial structuring. Rob is currently Chairman of the Perron Institute and was previously on the Takeovers Panel.
Paul Fry
Non-Executive Director
Paul was a former Partner of Ernst and Young and PwC in Australia and Canada and consults to companies in a broad range of industries. Paul’s expertise centres around public markets, capital raisings, governance, risk management and corporate transactions. He has been involved with numerous entities listed on the ASX.
Dr Anton Uvarov PhD, MBA
Non-Executive Director
Dr Uvarov has significant experience in the healthcare industry with a particular focus on biotechnology sector. Dr Uvarov started his career in biotechnology investments as an equities analyst with Citigroup and has co-founded numerous publicly listed companies in Australia, including Dimerix (ASX: DXB), Actinogen Medical (ASX: ACW), Neuroscientific Biopharmaceuticals (ASX: NSB), and most recently BlinkLab (ASX: BB1). Anton is currently an Executive Director at BlinkLab and Non-Executive Director at Patrys (ASX: PAB).
Clarke Barlow BCom, MAICD
Non-Executive Director
Mr. Barlow is a Financial Adviser and Capital Markets Specialist with over 20 years’ experience in the Financial Services Industry in Australia and the United Kingdom. Clarke has extensive experience providing corporate advisory services for companies listed on the ASX across a variety of industries, with a particular focus on growth opportunities in the Biotechnology, Technology, Industrial and Resources industries.
Management
Leadership Team
Nathan Smith
CEO
Mr. Smith’s career includes leadership positions at Cell Therapies Pty Ltd where he served as Director of Business Development as well as key roles at Genzyme Corporation (USA), Mesoblast Inc. (USA), GlaxoSmithKline (USA), and other leading companies in the cell therapy space. Throughout his career, Nathan has led programs across the full therapeutic lifecycle, including pre-clinical development and clinical trials, navigating the regulatory pathway in multiple jurisdictions and the commercial supply of products.
Dr Marian Sturm FFSc (RCPA), PhD, MSc, BSc Hons CSA & Chair of Advisory Board
Chief Scientific Officer
An expert in the research, operational and clinical development of cellular treatments, with over 40 years experience, Marian has been involved in the manufacturing of therapeutic goods for over 20 years and was a member of the TGA Advisory Committee on Biologics since its inauguration in 2012 to 2022.
Prof Catherine Cole MBBS, FRACP, FRCPA
Chief Medical Officer
Cathy has 35 years of experience in clinical paediatric haematology, oncology and stem cell transplant, managing patients as part of the large international cooperative clinical research group - The Children’s Oncology Group. During this time she served on the TGA Advisory Committee for Prescription Medicines (2006-2012), and The Pharmaceutical Benefits Advisory Committee (2013-2017).
StemSmart™: Advancing Stem Cell Therapy
A patented, high-quality platform for immune disease treatment
StemSmart™ is a globally patented technology designed to enhance the safety and efficacy of mesenchymal stem cell (MSC) therapies. Manufactured under GMP standards with a TGA product manufacturing licence, StemSmart™ products are consistently produced using a proprietary process that primes cells for stronger responses to inflammation. Early Phase 2 trial results in refractory Crohn’s disease indicate StemSmart™ MSC is potent, efficacious, and safe.